Outcomes of patients with R/R FLT3(mut+) AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation. Hou HA, Getta B, Ahn JS, Elsouda D, et al. Leuk Res 2026;162:108186.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hou HA, Getta B, Ahn JS, Elsouda D, et al. Outcomes of patients with R/R FLT3(mut+) AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation. Leuk Res 2026;162:108186.
PMID: 41722526